May be taken with or without food. May be taken before or after meals.
|
Obstructive disease of the gastrointestinal tract, reflux oesophagitis, severe ulcerative colitis, unstable CV status in acute haemorrhage, glaucoma, obstructive uropathy, myasthenia gravis, salmonella dysentery. Infants <6 months. Lactation.
|
Patient with coronary artery disease, heart failure, hypertension, tachyarrhythmia (e.g. thyrotoxicosis), hyperthyroidism, autonomic neuropathy, known or suspected prostatic hyperplasia, mild to moderate ulcerative colitis, altered physical or mental abilities;, fever. Patients undergoing cardiac surgery. Presence of increased environmental temperature (e.g. hot weather, exercise). Renal and hepatic impairment. Children and elderly. Pregnancy. Patient Counselling This drug may cause drowsiness or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor urinary output, anticholinergic effects, and gastrointestinal symptoms.
|
Significant: Drowsiness, blurred vision, diarrhoea, heat prostration (in increased environmental temperature), psychosis and delirium (especially elderly and mentally ill patients).
Cardiac disorders: Palpitations, tachyarrhythmia.
Eye disorders: Mydriasis, cycloplegia, photophobia.
Gastrointestinal disorders: Dry mouth, thirst, constipation, nausea, vomiting, abdominal pain, abdominal distension, dyspepsia.
General disorders and administration site conditions: Fatigue, asthenia.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Dizziness, sedation, headache, nervousness.
Psychiatric disorders: Insomnia.
Renal and urinary disorders: Dysuria.
Reproductive system and breast disorders: Suppressed lactation.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, nasal congestion, reduced bronchial secretions.
Skin and subcutaneous tissue disorders: Rash, allergic dermatitis, erythema.
Vascular disorders: Flushing.
|
|
|
Enhanced adverse effect with other anticholinergic agents (e.g. amantadine, quinidine, antihistamines, phenothiazine, benzodiazepines, MAOIs, meperidine, nitrates and nitrites, TCAs, sympathomimetic agents). May antagonize the effects of antiglaucoma agents. May diminish the therapeutic effect of gastrokinetic drugs (e.g. metoclopramide). Altered absorption with antacids.
|
|
|
A03AA07 - dicycloverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
|
Sign Out
